Table 2.
Effects of COS on liver and kidney functions in d-gal-treated mice.
| Groups | Liver Function | Kidney Function | |||
|---|---|---|---|---|---|
| ALP (U/L) | ALP (U/L) | AST (U/L) | CREA (μmol/L) | UA (μmol/L) | |
| Normal | 50.08 ± 5.46 | 20.88 ± 3.17 | 53.79 ± 4.40 | 51.46 ± 3.08 | 125.24 ± 9.52 |
| Model | 82.26 ± 3.09 # | 28.20 ± 4.39 # | 78.51 ± 3.77 # | 61.49 ± 5.53 # | 162.55 ± 8.93 # |
| VE | 69.26 ± 6.05 * | 22.05 ± 4.02 * | 68.61 ± 5.24 * | 58.36 ± 6.28 | 142.83 ± 7.76 * |
| COS-L | 68.28 ± 4.57 * | 25.59 ± 3.63 | 65.15 ± 4.21 * | 55.51 ± 3.36 | 160.33 ± 5.55 |
| COS-M | 64.07 ± 3.29 * | 20.45 ± 2.05 * | 60.08 ± 2.26 * | 53.14 ± 3.70 * | 139.13 ± 11.03 * |
| COS-H | 58.85 ± 4.83 * | 19.10 ± 1.52 * | 57.01 ± 3.67 * | 51.99 ± 1.09 * | 130.39 ± 8.65 * |
Data represent means ± SD (n = 8). # p < 0.05 compared with the normal group; * p < 0.05 compared with the model group.